Home>>Signaling Pathways>> Tyrosine Kinase>> ROR>>GSK2981278
GSK2981278 Catalog No.GC13905

RORγ-selective inverse agonist

Size Price Stock Qty
5mg
$96.00
In stock
10mg
$166.00
In stock
25mg
$363.00
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 1474110-21-8 SDF
Chemical Name N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)methoxy]-benzenesulfonamide
Canonical SMILES OCC1=CC(S(N(CC(C)C)C2=CC=C(CC)C=C2)(=O)=O)=CC=C1OCC3CCOCC3
Formula C25H35NO5S M.Wt 461.6
Solubility ≤15mg/ml in ethanol;5mg/ml in DMSO;30mg/ml in dimethyl formamide Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Background

GSK2981278 is a RORγ-selective inverse agonist.

RAR-related orphan receptor gamma (RORγ) is a protein that in humans is encoded by the RORC gene. The RORγ protein is a DNA-binding transcription factor and is a member of the NR1 subfamily of nuclear receptors.

In vitro: Previous study found that GSK2981278 had no significant effect on RORα-dependent activation, indicating its selectivity for RORγ. GSK2981278 also demonstrated 10-fold greater potency for IL-17A inhibition than its analogs of GSK3038548 and GSK3038549. In addition, authors examined the effect of GSK2981278 on endogenous il17a expression in Jurkat cells. Results showed that GSK2981278 could repress the activation of il17a by RORγt in a dose-responsive manner [1].

In vivo: In previous study, the imiquimod (IMQ) mouse model was employed to demonstrate efficacy of GSK2981278 in a psoriaform-like mouse model. Results showed that the topical application of IMQ could induce and exacerbate psoriasis-like chronic skin inflammation in mice. Next, mice were treated topically with GSK2981278 for three days, after which mice continued to receive compound for the duration of the study. It was found that GSK2981278 was undetectable in serum at harvest, suggesting that systemic exposure was minimal. In addition, mice exposed to GSK2981278 exhibited reduced skin redness and scaling, as well as decreased hyperplasia [1].

Clinical trial: The study of safety and efficacy of topical GSK2981278 ointment in plaque psoriasis has been finished but there is no results released [2].

References:
[1] Smith SH et al.  Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin. PLoS One. 2016 Feb 12;11(2):e0147979.
[2] https://clinicaltrials. gov/ct2/show/NCT02548052 term=GSK2981278&rank=2